Cerenion announces 200 patients measured in Finland

The clinical multisite study program that originally started with a small pilot of 10 cardiac arrest patients measured at the Intensive Care Unit (ICU) of Oulu University Hospital has now grown to a body of over 200 measured patients across several sites in Finland. The body of measurements provides clinical evidence on the Cerenion C-Trend(TM) Index as a measure of brain condition and function for a number of different patient groups.

“Extensive clinical studies and solid scientific evidence are extremely important for us as we are now moving from novel research to a practical product,” said Dr. Jukka Kortelainen, Chief Medical Officer and Co-founder at Cerenion. “The reception for the technology we are developing and interest in its potential applications has been very encouraging for us on this path,” he continued.

Cerenion appreciates all its partners for making this clinical study program possible. The first products with Cerenion C-Trend™ technology are expected during 2019. If you are interested in research collaboration please get in touch with the company.

Cerenion Oy develops the world’s ?rst practical method for measuring the brain function of intensive care patients. Cerenion C-Trend™ technology (pat. pend.) aims to reveal the status of the brain as one simple score – at the bed-side and without requiring any changes to the care of the patient. The solution works by combining standard EEG-measurement with advanced machine learning algorithms and artificial intelligence. The technology has the potential of improving both the quality and the cost of intensive care.

Contact person

Jukka Kortelainen
Chief Medical Officer, Co-founder, Cerenion